Please login to the form below

Not currently logged in
Email:
Password:

immunodeficiency

This page shows the latest immunodeficiency news and features for those working in and with pharma, biotech and healthcare.

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

The collaboration builds on Plasticell’s work with Professor Adrian Thrasher from UCL ICH, who has led clinical development of gene therapies for Severe Combined Immunodeficiencies (SCIDs), Wiscott-Aldrich Syndrome (WAS)

Latest news

  • GSK hands rare disease assets over to Orchard GSK hands rare disease assets over to Orchard

    severe combined immunodeficiency (ADA-SCID) or ‘bubble boy’disease - might do better outside the company.

  • NICE backs GSK’s ‘bubble baby’ gene therapy NICE backs GSK’s ‘bubble baby’ gene therapy

    NICE backs GSK’ s ‘ bubble baby’ gene therapy. Strimvelis will treat children under the NHS for immunodeficiency. ... Strimvelis was approved by the European Medicines Agency (EMA) last year to treat severe combined immunodeficiency due to

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1).

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    GlaxoSmithKline (GSK) got the green light from the CHMP for Strimvelis (GSK2696273) as a treatment for rare disease ADA-SCID - severe combined immunodeficiency due to adenosine deaminase deficiency - which is also

  • Mixed news for gene therapies at ASH conference Mixed news for gene therapies at ASH conference

    GlaxoSmithKline (GSK) reported positive results in a trial of a gene therapy for Wiskott– Aldrich syndrome (WAS), a rare genetic disorder that results in immunodeficiency and complication such as cancer. ... The successful trial comes after GSK became

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    These are: Primary Immunodeficiency Diseases (PID – causes severe infections); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP – causes of loss of limb function/disability); bleeding disorders (haemophilia and related conditions);

  • Health on instalment Health on instalment

    years. Initial disease targets include cancer, neuromuscular disease, haemophilia, immunodeficiencies and blindness.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics